The European Commission (EC) has authorized the extension of the label for all metformin-containing products for the treatment of type 2 diabetes.
This decision is based on data provided by companies including German pharma major Merck KGaA (MRK: DE), a firm that will benefit through its Glucophage portfolio and Glucovance (glyburide and metformin).
The label change lifts the contraindication for stable moderate renal failure chronic kidney disease (CKD) stage 3, but adds some dose limitations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze